Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

18 Aug 2021

Abstract excerpt

To the Editor: The variable efficacy of the interleukin-6 receptor antagonist tocilizumab against Covid-19, as shown most recently in the results of REMAP-CAP reported by Gordon et al. 1 and the results of the COVACTA trial reported by Rosas et al. 2 (April 22 issue), may reflect the fact that interleukin-6 has a dual role.Interleukin-6 stimulates desirable antibody production by immune cells that express...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Respiratory viral infections research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34407334
DOI: 10.1056/nejmc2108482

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19PMID 34407334Read ↗

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity Read ↗

Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients'.Semantic proximity Read ↗

Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19Semantic proximity Read ↗

Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19-Related Acute Respiratory Distress Syndrome.Semantic proximity Read ↗

[Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia].Semantic proximity Read ↗

Genetic inhibition of interleukin-6 receptor signaling and Covid-19Semantic proximity Read ↗

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumoniaSemantic proximity Read ↗

Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 PatientsSemantic proximity Read ↗

Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirementSemantic proximity Read ↗

A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19Semantic proximity Read ↗

Single Versus Multiple Doses of Tocilizumab in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19): A Two-center, Retrospective Cohort StudySemantic proximity Read ↗

Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.